First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
06 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
Expanding the Success of Famileo: Still Bringing Residents and Families Together!
05 janv. 2022 14h42 HE
|
Signature Healthcare
Louisville, KY., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Signature HealthCARE’s residents and families have been nothing short of resilient during our on-going pandemic in a number of ways, including...
First Wave BioPharma to Participate in Two Investor Conferences in January 2022
04 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement
31 déc. 2021 08h47 HE
|
Vir Biotechnology, Inc.
– Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein – – Together with recent pseudo- and live virus results, additional preclinical data...
Lui Franciosi Sends His Season Greetings and Best Wishes for 2022
28 déc. 2021 21h32 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia , Dec. 28, 2021 (GLOBE NEWSWIRE) -- Lui Franciosi would like to send his season greetings and best wishes for a successful 2022 to all clients and friends. It has been...
Lui Franciosi Looking at the Effects of the Omicron Variant Surge on Seniors During this COVID-19 Pandemic
28 déc. 2021 21h25 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be assessing the effects of the Omicron variant surge on...
Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant
23 déc. 2021 08h03 HE
|
Codex DNA, Inc.
SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic...
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
23 déc. 2021 07h30 HE
|
Achiko AG
2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and...
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
22 déc. 2021 09h12 HE
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Rapid-Trace Announces New Contact Tracing Partnerships
21 déc. 2021 14h00 HE
|
Rapid-Trace
ST. PETERSBURG, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rapid-Trace, a leading contact tracing company, is excited to announce partnerships with the following colleges and universities: North...